Anzeige
Mehr »
Donnerstag, 07.08.2025 - Börsentäglich über 12.000 News
Große CEO-Enthüllung: Analysten sehen +56% Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DZJ0 | ISIN: US44148G2049 | Ticker-Symbol:
NASDAQ
06.08.25 | 21:56
1,310 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
HOTH THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
HOTH THERAPEUTICS INC 5-Tage-Chart
GlobeNewswire (Europe)
158 Leser
Artikel bewerten:
(1)

Silo Pharma, Inc.: Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Technology Co-Developed by the U.S. Department of Veterans Affairs and Emory University

NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into a non-binding letter of intent to form a strategic 50:50 joint venture with Hoth Therapeutics, Inc. (Nasdaq: HOTH) to develop and commercialize a potential treatment for obesity and metabolic disease based on technology Hoth has exclusively licensed from the U.S. Department of Veterans Affairs (VA) that was co-developed by the VA and Emory University.

The novel therapeutic platform centers on glial cell line-derived neurotrophic factor (GDNF), a VA-invented biologic with demonstrated anti-obesity effects and metabolic regulation in preclinical models. The platform is protected under U.S. Patent No. 10,052,362 and targets multiple high-burden conditions, including non-alcoholic fatty liver disease (NAFLD), type 2 diabetes, and central obesity.

"With obesity at epidemic levels and no curative therapies available, we believe the VA's biologic GDNF is potentially a game-changer," said Eric Weisblum, CEO of Silo Pharma. "We believe that our potential JV collaboration with Hoth aligns with our mission to accelerate groundbreaking science into human trials."

"This VA-originated obesity technology has the potential to disrupt a $16 billion market and deliver life-changing impact for millions, including veterans disproportionately affected by metabolic disorders," added Robb Knie, CEO of Hoth Therapeutics. "We are proud to partner with Silo Pharma in an effort to bring this innovation to the public."

Deal Highlights:

?Exclusive U.S. License from the U.S. Department of Veterans Affairs covering all fields of use
?50/50 joint venture structure with equal equity and governance participation
?Lead indication: Obesity and NAFLD - conditions with prevalence among both civilian and veteran populations

Unmet Need:
Obesity affects over 40% of U.S. adults and is a leading risk factor for diabetes, cardiovascular disease, and liver failure. Veterans are especially impacted due to chronic inflammation, PTSD-linked metabolic disruption, and access challenges to effective care. There are no approved curative biologics targeting the neuroinflammatory root of obesity, a gap that this VA-originated technology is uniquely positioned to fill.

Strategic Alignment:
The partnership leverages:

?The clinical infrastructure and public mission of the VA
?Hoth's regulatory and development expertise
?Silo's translational capabilities and capital efficiency

About Silo Pharma

Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo's research is conducted in collaboration with leading universities and laboratories. silopharma.com

Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words "could", "believe", "anticipate", "intend", "estimate", "expect", "may", "continue", "predict", "potential", and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. ("Silo" or "the Company") to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company's technology platforms, retaining and expanding the Company's customer base, fluctuations in consumer spending on the Company's products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.

Contact
800-705-0120
investors@silopharma.com


© 2025 GlobeNewswire (Europe)
Tech-Aktien mit Crash-Tendenzen
Künstliche Intelligenz, Magnificent Seven, Tech-Euphorie – seit Monaten scheint an der Börse nur eine Richtung zu existieren: nach oben. Doch hinter den Rekordkursen lauert eine gefährliche Wahrheit. Die Bewertungen vieler Tech-Schwergewichte haben historische Extremniveaus erreicht. Shiller-KGV bei 39, Buffett-Indikator auf Allzeithoch – schon in der Dotcom-Ära war der Markt kaum teurer.

Hinzu kommen euphorische Anlegerstimmung, IPO-Hypes ohne Substanz, kreditfinanzierte Wertpapierkäufe in Rekordhöhe und charttechnische Warnsignale, die Erinnerungen an 2000 und 2021 wecken. Gleichzeitig drücken geopolitische Risiken, Trumps aggressive Zollpolitik und saisonale Börsenschwäche auf die Perspektiven.

Die Gefahr: Aus der schleichenden Korrektur könnte ein rasanter Crash werden – und der könnte vor allem überbewertete KI- und Chipwerte hart treffen.

In unserem kostenlosen Spezial-Report zeigen wir Ihnen, welche Tech-Aktien am stärksten gefährdet sind und wie Sie Ihr Depot vor dem Platzen der Blase schützen könnten.

Holen Sie sich den neuesten Report!

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.